Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03214354 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Study acronym: Sickle-AID
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv7
  2. Site contact updatedv6
  3. Primary completion date: Jul 2023 to Jul 2028
    • Study completion date: Jul 2024 to Jul 2028
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Primary completion date: Jul 2021 to Jul 2023
    • Study completion date: Jul 2023 to Jul 2024
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.
Trial Details
NCT Number NCT03214354
Lead Sponsor University of Calgary
Conditions
(from sponsor)		 Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
Related terms Anemia, Sickle Cell, Red-Cell Aplasia, Pure
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov